SubSUF-ER - Management of moderate to severe monotraumatic pain with sublingual Sufentanil in an emergency situation.

Conditions

trauma to the lower or upper limb

Brief summary

the variation in pain rating measured by the verbal numerical scale between T0 and T0+60 minutes

Detailed description

The tolerance profile will be assessed by analyzing the occurrence of any adverse event, mainly (hypotension, bradycardia, respiratory depression, sweating, drowsiness, nausea and/or vomiting, dizziness), Variation of pain rating measured by verbal numerical scale between T0 and T0+15min; T0+30 min; T0+45 min; T0 + 60 min T0+120 min; T0+180 minutes, Variation of pain rating measured by verbal numerical scale between T0 and TEVmax. Pain intensity assessed at different times, T0, T0 + 15min, T0 + 30min, T0 + 45min, T0 + 60min, T0 + 120min, T0 + 180min., Measurement of variations in hemodynamic parameters: blood pressure, pulse, oxygen saturation, respiratory rate., At the end of the study at T0 + 180 min, patients will be asked to give their assessment via a verbal satisfaction scale ranging from 0 "Very dissatisfied" to 10 "Very satisfied": - of the permucosal product tested using a product assessment questionnaire. - Of the pain management in general

Related papers

No related papers found yet.

Interventions

DRUGKETOPROFENE AGUETTANT 100 mg

DRUGsolution pour perfusion

DRUGMORPHINE (CHLORHYDRATE) RENAUDIN 10 mg/ml

DRUGsolution injectable

DRUGCODOLIPRANE 500 mg/30 mg

DRUGcomprimé

DRUGTRAMADOL ARROW 100 mg/2 mL

DRUGsolution injectable/pour perfusion

DRUGACUPAN 20 mg/2 mL

DRUGDzuveo 30 micrograms sublingual tablet

DRUGIXPRIM 37

DRUG5 mg/325 mg

DRUGcomprimé pelliculé

DRUGKALINOX 50 %/ 50 % Gas zur medizinischen Anwendung

DRUGdruckverdichtet

DRUGPARACETAMOL AGUETTANT 10 mg/ml

DRUGDOLIPRANE 1000 mg

DRUGgélule

DRUGDOLIPRANE 500 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the variation in pain rating measured by the verbal numerical scale between T0 and T0+60 minutes	—

Secondary

Measure	Time frame
The tolerance profile will be assessed by analyzing the occurrence of any adverse event, mainly (hypotension, bradycardia, respiratory depression, sweating, drowsiness, nausea and/or vomiting, dizziness), Variation of pain rating measured by verbal numerical scale between T0 and T0+15min; T0+30 min; T0+45 min; T0 + 60 min T0+120 min; T0+180 minutes, Variation of pain rating measured by verbal numerical scale between T0 and TEVmax. Pain intensity assessed at different times, T0, T0 + 15min, T0 + 30min, T0 + 45min, T0 + 60min, T0 + 120min, T0 + 180min., Measurement of variations in hemodynamic parameters: blood pressure, pulse, oxygen saturation, respiratory rate., At the end of the study at T0 + 180 min, patients will be asked to give their assessment via a verbal satisfaction scale ranging from 0 "Very dissatisfied" to 10 "Very satisfied": - of the permucosal product tested using a product assessment questionnaire. - Of the pain management in general	—

Measure

Time frame

The tolerance profile will be assessed by analyzing the occurrence of any adverse event, mainly (hypotension, bradycardia, respiratory depression, sweating, drowsiness, nausea and/or vomiting, dizziness), Variation of pain rating measured by verbal numerical scale between T0 and T0+15min; T0+30 min; T0+45 min; T0 + 60 min T0+120 min; T0+180 minutes, Variation of pain rating measured by verbal numerical scale between T0 and TEVmax. Pain intensity assessed at different times, T0, T0 + 15min, T0 + 30min, T0 + 45min, T0 + 60min, T0 + 120min, T0 + 180min., Measurement of variations in hemodynamic parameters: blood pressure, pulse, oxygen saturation, respiratory rate., At the end of the study at T0 + 180 min, patients will be asked to give their assessment via a verbal satisfaction scale ranging from 0 "Very dissatisfied" to 10 "Very satisfied": - of the permucosal product tested using a product assessment questionnaire. - Of the pain management in general

—

Countries

France

Outcome results

None listed